GlassScriptPhysician profile
Gina Lazzara
NPI 1598328775
$6,379.98
in general payments reported to CMS, 2019-2025
22 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $537 · 2023: $913 · 2024: $3,874 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,213 · Travel and Lodging: $533 · Education: $96.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,213.37 |
| Travel and Lodging | $533.24 |
| Education | $96.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,011.70 | 2024-2025 | Cardiomems, Ensite, Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic, INC. | $882.83 | 2022-2025 | Corevalve Evolut R, Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan |
| Abiomed | $867.29 | 2024 | Impella |
| Boston Scientific Corporation | $835.85 | 2023-2024 | Watchman Flx, Opticross, Avvigo Guidance System |
| Amgen INC. | $727.51 | 2022-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.38 | 2022-2025 | Jardiance |
| Edwards Lifesciences Corporation | $294.97 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), The Edwards Sapien 3 Valve With Alterra Adaptive Prestent System |
| Pfizer INC. | $223.88 | 2022-2025 | Eliquis, Vyndaqel |
| Alnylam Pharmaceuticals INC. | $192.14 | 2022-2025 | |
| Terumo Medical Corporation | $151.30 | 2024 | Tr Band, Angio-Seal |
| Lexicon Pharmaceuticals, INC. | $130.43 | 2023 | Inpefa |
| Janssen Pharmaceuticals, INC | $113.88 | 2024 | Xarelto |
| Philips North America LLC | $112.91 | 2024 | (Bq9) Coronary Ivus |
| Astrazeneca Pharmaceuticals LP | $84.20 | 2024-2025 | Wainua, Farxiga |
| Actelion Pharmaceuticals US, INC. | $78.57 | 2024 | Opsumit, Uptravi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $76.82 | 2025 | Attruby |
| E.R. Squibb & Sons, L.L.C. | $46.63 | 2025 | Camzyos |
| Lantheus Medical Imaging, INC. | $43.27 | 2022-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $42.45 | 2024 | Arcalyst |
| Novartis Pharmaceuticals Corporation | $37.31 | 2024 | |
| Sanofi-Aventis U.S. LLC | $18.29 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.37 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Lazzara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.